CLAIMS

1. The use of a composition comprising Torasemide or a salt, or sustained release formulation thereof, for the manufacture of a medicament for treating Alzheimer's disease (AD), ~~or an AD related disorder~~ senile dementia of AD type (SDAT), Lewy body dementia, vascular dementia, mild cognitive impairment (MCI), age-associated memory impairment (AAMI), amyotrophic lateral sclerosis (ALS) or spinal cord injury (SCI).

2. The use according to claim 1, wherein said medicament further comprises a composition comprising at least one compound selected from Sulfisoxazole, Methimazole, Prilocaine, Dyphylline, Quinacrine, Carbenoxolone, Acamprosate, Aminocaproic acid, Baclofen, Cabergoline, Diethylcarbamazine, Cinacalcet, Cinnarizine, Eplerenone, Fenoldopam, Leflunomide, Levosimendan, Sulodexide, Terbinafine, Zonisamide, Etomidate, Phenformin, Trimetazidine, Mexiletine, Ifenprodil, Moxifloxacin, or Bromocriptine, Torasemide, or salt(s), or sustained release formulation(s) thereof.

3. The use according to ~~any one of the preceding~~ claims 1 or 2, wherein said medicament comprises at least one of the following combinations of compounds:
   - Baclofen and Torasemide,
   - Sulfisoxazole and Torasemide,
   - Eplerenone and Torasemide,
   - Terbinafine and Torasemide,
   - Baclofen and Trimetazidine and Torasemide,
   - Baclofen and Cinacalcet and Torasemide,
   - Baclofen and Acamprosate and Torasemide,
   - Sulfisoxazole and Trimetazidine and Torasemide and Zonisamide,
   - Sulfisoxazole and Mexiletine and Torasemide and Cinacalcet,
   - Baclofen and Acamprosate and Torasemide and Diethylcarbamazine, or
   - Baclofen and Acamprosate and Torasemide and Ifenprodil,
   - or salt(s), or sustained release formulation(s) thereof.

4. The use according to any one of ~~the preceding~~ claims 1 to 3, wherein said compositions further comprise a pharmaceutically acceptable carrier or excipient.

5. The use according to any one of claims 2 to 4, wherein the compounds in said medicament are formulated together ~~or separately~~.

~~6. The use of any one of the preceding claims, wherein said composition(s) is (are) formulated to be administered repeatedly to the subject.~~

~~7. A composition comprising Torasemide or salt(s), or sustained release formulation(s) thereof, in combination with at least one second compound selected from Sulfisoxazole, Methimazole, Prilocaine, Dyphylline, Quinacrine, Carbenoxolone, Acamprosate, Aminocaproic acid, Baclofen, Cabergoline, Diethylcarbamazine, Cinacalcet, Cinnarizine, Eplerenone, Fenoldopam, Leflunomide, Sulodexide, Terbinafine, Zonisamide, Etomidate, Phenformin, Trimetazidine, Mexiletine, Bromocriptine, Ifenprodil, and Moxifloxacin, or salt(s) or sustained release formulation(s) thereof, and a pharmaceutically acceptable excipient.~~

~~8. The composition of claim 7, wherein said composition comprises at least one of the following combinations of compounds:~~

~~— Baclofen and Torasemide,~~

~~— Sulfisoxazole and Torasemide,~~

~~— Eplerenone and Torasemide,~~

~~— Terbinafine and Torasemide,~~

~~— Baclofen and Trimetazidine and Torasemide,~~

~~— Baclofen and Cinacalcet and Torasemide,~~

~~— Baclofen and Acamprosate and Torasemide,~~

~~— Sulfisoxazole and Trimetazidine and Torasemide and Zonisamide,~~

~~— Sulfisoxazole and Mexiletine and Torasemide and Cinacalcet,~~

~~— Baclofen and Acamprosate and Torasemide and Diethylcarbamazine, or~~

~~— Baclofen and Acamprosate and Torasemide and Ifenprodil,~~

~~or salt(s) or sustained release formulation(s) thereof; and a pharmaceutically acceptable excipient.~~